歌礼制药完成ASC47联合司美格鲁肽治疗肥胖症治疗临床首批给药
5月20日，歌礼制药-B（01672）发布公告，宣布其自主研发的脂肪靶向小分子THRβ激动剂ASC47联合司美格鲁肽治疗肥胖症的美国临床研究已完成首批受试者给药。
该研究旨在评估超长效皮下注射ASC47单次给药联合司美格鲁肽（0.5毫克，每周一次）四次给药的治疗方案在肥胖受试者中的安全性及初步疗效。ASC47单药疗法在Ib期肥胖受试者研究中显示出长达40天的半衰期，并且在头对头比较的饮食诱导肥胖小鼠模型中，低剂量ASC47与司美格鲁肽联合用药比司美格鲁肽单药疗法多减重56.7%，且不减肌。
ASC47-103研究是一项在美国开展的随机、双盲、安慰剂对照研究，受试者将接受不同剂量的ASC47（10毫克、30毫克和60毫克）或注射等量安慰剂，并同时接受四次司美格鲁肽的注射。该联合用药临床研究的顶线数据预计将于2025年第四季度公布。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10